Skip to main content
Premium Trial:

Request an Annual Quote

We'd Like to Thank the Academy

Derek Lowe has a post at his In the Pipeline blog defending PNAS, which he says gets a bad rap from scientists. "The reason people are down on PNAS is the way that members of the National Academy can, if they choose, sort of jam things into the journal through a side entrance," he writes. But basic math shows that for non-academy members who are published there (those papers make up about 40 percent of the pub's content), the competition is downright brutal, Lowe says -- likely resulting in top-notch literature. He adds, "I think, myself, that the advantage of letting members publish unusual or possibly controversial work outweighs the temptation to fill the journal with junk."


The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.